News | October 22, 2006

Pill-Taking Habits Important but Tough to Change

Getting patients to take their medications as directed can cut health-care costs, but improving their pill-taking habits can be difficult, researchers say.

As part of their research into the issue, a team at the University of Chicago conducted two studies. The first found that patients with mild to moderate ulcerative colitis who consistently took a prescribed medication — 5-aminosalicyclic acid (5-ASA) — had 12.5 percent lower medical costs than patients who did not comply with the therapy.

"Patients with ulcerative colitis often struggle to comply with current 5-ASA treatments because they have to take multiple pills throughout the day. This study shows that following your doctor's advice, even when it's inconvenient, is worth the extra effort," study director Dr. Sunanda Kane, an associate professor of medicine, said in a prepared statement.

She and her colleagues found that young and old patients were least likely to comply with their 5-ASA therapy. Compliance rates were: 57 percent for patients aged 40 to 64; 55 percent for those aged 18 to 40; 41 percent for those over age 65; and 35 percent for those under age 18. Males and females had similar compliance rates.

"What if we simplify a patient's regimen with a reduced pill burden, ideally a once-daily treatment? Would patients be more likely to comply, and would that lower health care expenses?" Kane wondered.

But a second study conducted by Kane and her team suggested that simply reducing pill count may not be enough to improve patient compliance. The study of 1,680 ulcerative colitis patients found that the number of prescribed pills per day had no effect on compliance.

The patients took either 4, 6, 9 or 16 pills a day. In all four groups, compliance decreased from 100 percent at the start of the study to about 65 percent after three months.

"What it all means is that we have a lot more to learn about patient behaviors," Kane said.

The findings from both studies were expected to be presented this week at the American College of Gastroenterology annual meeting, in Las Vegas. The cost study was funded by Shire Pharmaceuticals, and the dosing study by Proctor & Gamble.

Related Content

News | Image Guided Radiation Therapy (IGRT) | July 31, 2017
Elekta’s magnetic resonance radiation therapy (MR/RT) system will be the subject of 21 abstracts at the 59th American...
News | Image Guided Radiation Therapy (IGRT) | July 13, 2017
Elekta and Sunnybrook Health Sciences Centre have initiated installation of Elekta’s MR-linac, an investigational...
First New York Metropolitan Hospital Treats Cancer Patients With Accuray Radixact System
News | Image Guided Radiation Therapy (IGRT) | July 03, 2017
Accuray Inc. and Montefiore Einstein Center for Cancer Care (MECCC), part of the Montefiore Health System (MHS),...
IUCT Oncopole Installs First Radixact Radiotherapy System in France
News | Intensity Modulated Radiation Therapy (IMRT) | June 20, 2017
Accuray Inc. announced that the University Cancer Institute of Toulouse Oncopole (IUCT Oncopole) in Toulouse, France,...
Henry Ford Cancer Institute First in World to Install Viewray MRIdian Linac
News | Image Guided Radiation Therapy (IGRT) | June 19, 2017
The Henry Ford Cancer Institute is the first in Michigan – and first in the world – to offer patients advanced...
News | Image Guided Radiation Therapy (IGRT) | May 24, 2017
The University Medical Centre (UMC) Utrecht in the Netherlands recently treated the first patient as part of a clinical...
Mevion and medPhoton Bring Advanced Cone Beam CT Imaging to Proton Therapy
News | Proton Therapy | May 04, 2017
Mevion Medical Systems announced a strategic agreement with medPhoton GmbH to integrate ImagingRing, an innovative cone...
ViewRay, MRIdian Linac system, FDA 510k approval, MRI-guided radiation therapy
Technology | Image Guided Radiation Therapy (IGRT) | February 27, 2017
February 27, 2017 — ViewRay Inc. announced that the company received 510(k) clearance from the U.S.
Overlay Init